BLI 1100

Drug Profile

BLI 1100

Alternative Names: BLI1100

Latest Information Update: 18 Nov 2015

Price : $50

At a glance

  • Originator Braintree Laboratories
  • Class Antiacnes
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acne vulgaris

Most Recent Events

  • 01 Oct 2015 Phase-II clinical trials in Acne vulgaris (In adolescents, In adults) in USA (Topical, Gel) (NCT02604680)
  • 27 Aug 2015 No recent reports on development identified - Phase-II for Acne vulgaris in USA (Topical, Cream)
  • 02 Aug 2013 Braintree Laboratories completes enrolment in its phase II trial for Acne vulgaris in USA (NCT01815450)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top